Skip to content
HowShorted

ATOSSA THERAPEUTICS, INC. short interest in 2023

In 2023, ATOSSA THERAPEUTICS, INC.'s disclosed short interest ran from 7.17% of shares outstanding on 13 Jan 2023 to 5.07% on 29 Dec 2023, a change of -2.10 percentage points. The year's high was 7.17% on 13 Jan 2023 and its low 4.98% on 30 Nov 2023, averaging 6.17% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 35.16 days on 14 Apr 2023. Full history: ATOSSA THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for ATOSSA THERAPEUTICS, INC. in 2023

2023 in figures

Start of year
7.17% (13 Jan 2023)
End of year
5.07% (29 Dec 2023)
Change
-2.10 pp
High
7.17% (13 Jan 2023)
Low
4.98% (30 Nov 2023)
Average
6.17%
Highest days to cover
35.16 (14 Apr 2023)
SEC filings marked
8

Every report in 2023

ATOSSA THERAPEUTICS, INC. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20237.17%13.09
31 Jan 20236.94%11.90
15 Feb 20236.90%18.21
28 Feb 20236.75%28.23
15 Mar 20236.80%24.84
31 Mar 20236.67%29.7810-K filed, results (8-K)
14 Apr 20236.58%35.16
28 Apr 20236.38%27.68
15 May 20236.14%23.4610-Q filed, results (8-K)
31 May 20235.94%6.79
15 Jun 20235.73%13.23
30 Jun 20236.12%4.04
14 Jul 20236.89%7.57
31 Jul 20236.71%11.16
15 Aug 20236.64%15.7110-Q filed, results (8-K)
31 Aug 20236.52%19.75
15 Sep 20236.32%16.63
29 Sep 20235.77%15.15
13 Oct 20235.60%22.71
31 Oct 20235.29%26.73
15 Nov 20235.08%18.5010-Q filed, results (8-K)
30 Nov 20234.98%21.71
15 Dec 20235.03%27.15
29 Dec 20235.07%8.04

See also: ATOSSA THERAPEUTICS, INC.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.